Monoclonal Antibodies, the distribution is entrusted to Commissioner Arcuri

The decree of the Minister of Health Roberto Speranza for the 'Authorization for the temporary distribution of monoclonal antibody-based medicines for the treatment of COVID-19' has been published in the official gazette.

The temporary distribution of the monoclonal antibody bamlanivimab and the combination of monoclonal antibodies bamlanivimab-etesevimab, produced by the pharmaceutical company Eli Lilly, and the combination of monoclonal antibodies casirivimab-imdevimab of the pharmaceutical company Regeneron / Roche are authorized.

The distribution of drugs with monoclonal antibodies is carried out by the extraordinary Commissioner for the implementation and coordination of measures to contain and contrast the epidemiological emergency COVID-19.

This is foreseen by the decree of the Minister of Health 'Authorization for the temporary distribution of medicines based on monoclonal antibodies for the treatment of COVID-19' published in the official gazette.

For the year 2021, "in the forecast of the Ministry of Health, a fund has been set up with a budget of 400 million euros to be allocated to the purchase of anti SARS-CoV-2 vaccines and drugs for the treatment of COVID-19 ", reads the decree of the Ministry of Health, with reference to the budget law of 30 December 2020 n.178.